According to the European Society of Cardiology’s 2021 guidelines for heart failure, the first line medical therapy recommended for the treatment of heart failure with reduced ejection fraction (HFrEF) is represented by the angiotensin receptor-neprilysin inhibitor (ARNI) or angiotensin-converting enzyme inhibitor (ACE-I), beta-blocking agent, mineralocorticoid receptor antagonist (MRA), and the new recommendation of sodium-glucose co-transporter 2 (SGLT2) inhibitors such as dapagliflozin and empagliflozin unless the drugs are contraindicated or not tolerated [4,5,6]. Here, NR3C2 is linked to heart failure.